Medicine and Health Sciences Commons^™

Treatment Selection And Survival In Patients With Gray Zone Lymphoma; A Comprehensive Population-Based Analysis, Yazan Samhouri, Thejus T. Jayakrishnan, Lynna Alnimer, Veli Bakalov, Rodney E. Wegner, Cyrus Khan, Salman Fazal, John Lister

Hematology/Oncology and Stem Cell Therapy

Background and objectives: There are no treatment guidelines for gray-zone lymphoma (GZL), given the disease's rarity and being a relatively new entity. Our objective was to assess factors affecting treatment selection in GZL and its effect on survival, focusing on combined modality treatment (CMT) versus chemotherapy alone. Patients and methods: We identified 1047 patients with GZL treated with CMT or chemotherapy alone between 2004 and 2016 from the National Cancer Database (NCDB). We excluded patients without histologic confirmation of the diagnosis, those who did not receive chemotherapy, and those who started chemotherapy >120 days or radiation >365 days from diagnosis …